Industry News

The agreement adds to rising global demand for CDMO partnerships and may drive further capacity expansion, according to the company.

The investment supports a three-unit strategy spanning small molecules, peptides, and advanced therapies at sites in the U.S. and France.

The planned Philadelphia facility, combined with operations in Everett, Washington, is expected to boost isotope production capacity 20-fold by 2029.

The Rosenberg site upgrade targets growing demand for U.S.-based liquid and semi-solid drug manufacturing.

The new R&D hub is designed to streamline scale-up and simplify technology transfer for high-potency active pharmaceutical ingredients.

The collaboration focuses on transitioning manual regulatory T-cell manufacturing to a closed, scalable platform.

The new high-pressure technology is designed to improve reaction control, scalability, and safety for active pharmaceutical ingredient manufacturing.

The system is designed to increase manufacturing output while reducing costs and addressing key scalability bottlenecks, according to the company.

The facility will host up to 30 early-stage biotech companies and support drug development and manufacturing collaboration.

The funding will support development of a digital platform designed to model and optimize genomic medicine production.

The investment in Valanx Biotech targets site-specific conjugation technology designed to improve uniformity and stability of antibody-drug conjugates.

The newly approved facility is designed to support late-stage and commercial-scale viral vector production for cell and gene therapy programs.

The agreement supports development and clinical manufacturing of induced pluripotent stem cell-derived therapies targeting ocular and retinal diseases.

First announced in July 2025, the new Research Triangle Park site will provide formulation, analytical, and drug product development services for biopharma clients.

The investment aims to build local oral drug manufacturing capacity and support production of the investigational GLP-1 therapy orforglipron.

The collaboration supports controlled human infection model studies aimed at accelerating RSV vaccine development.

The project will expand plasma-derived therapy production capacity and add at least 300 jobs at the company’s Kankakee manufacturing site.

The extended agreement will increase manufacturing capacity in Houston to support demand for the approved Zynteglo beta-thalassemia gene therapy.

The CDMO expanded GMP analytical capabilities, including in vitro bioequivalence testing, to support early-stage development of inhaled and nasal therapies.

The investment will expand production, warehousing, and quality capabilities at the company’s Hengoed facility to strengthen medicine supply across the UK and Europe.

The submission follows completion of aseptic process simulation validation batches conducted under the revised EU GMP Annex 1 requirements.

The expanded BioMaP consortium agreement supports commercial-scale domestic production of two critical pharmaceutical ingredients using biosynthesis.

The company launched two cGMP facilities in Irvine, California, supporting formulation development, clinical manufacturing, and commercial production of tablets and capsules.

The system is designed to support commercial production of amorphous solid dispersions used to improve the bioavailability of poorly soluble drug candidates.

The new facility at Flatiron Park in Boulder will support process development and analytical services adjacent to the company’s peptide API manufacturing site.

The rational-design cell line reportedly delivers up to three-fold productivity gains while maintaining stability across modalities and scale-up.

The technology uses a novel protease and affinity tagging approach to simplify downstream purification of complex biologics.

The partnership adds 10 GMP production lines and 350,000 liters of reactor capacity to support clinical- through commercial-scale active pharmaceutical ingredient supply.

The deal grants Earendil exclusive rights to WuXi’s payload-linker platform, combining AI-driven antibody discovery with integrated antibody-drug conjugate manufacturing.

The CDMO will present on process analytical technology, digital manufacturing, and real-time analytics as part of FDA’s CBER Advanced Manufacturing Seminar Series.